A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.
- 17 Aug 2016 New trial record